Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration

Molecular Cancer

Short Communication

Andreas Roidl¹  Ernst Wagner¹  Annika Herrmann¹  Adam Hermawan¹  Prajakta Shirish Oak¹  Florian Kopp¹ 

[1] Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, Butenandtstrasse 5-13, 81377, Munich, Germany;

关键词: Salinomycin;    Cancer;    Migration;    Cell motility;    Metastasis;   

DOI  :  10.1186/1476-4598-13-16

 received in 2013-09-19, accepted in 2014-01-24,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundTumor spreading is the major threat for cancer patients. The recently published anti-cancer drug salinomycin raised hope for an improved treatment by targeting therapy-refractory cancer stem cells. However, an unambiguous role of salinomycin against cancer cell migration and metastasis formation remains elusive.FindingsWe report that salinomycin effectively inhibits cancer cell migration in a variety of cancer types as determined by Boyden chamber assays. Additionally, cells were treated with doxorubicin at a concentration causing a comparable low cytotoxicity, emphasizing the anti-migratory potential of salinomycin. Moreover, single-cell tracking by time-lapse microscopy demonstrated a remarkable effect of salinomycin on breast cancer cell motility. Ultimately, salinomycin treatment significantly reduced the metastatic tumor burden in a syngenic mouse tumor model.ConclusionsOur findings clearly show that salinomycin can strongly inhibit cancer cell migration independent of the induction of cell death. We furthermore demonstrate for the first time that salinomycin treatment reduces metastasis formation in vivo, strengthening its role as promising anti-cancer therapeutic.

【 授权许可】

Unknown   
© Kopp et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.